Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.23736/S0026-4806.20.06616-1 http://scihub22266oqcxt.onion/10.23736/S0026-4806.20.06616-1 32407051!?!32407051 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32407051&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Minerva+Med 2020 ; 111 (4): 362-364 Nephropedia Template TP {{tp|p=32407051|t=2020. Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?|pdf=|usr=}}{{32407051}} gab.com Text Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19 JO: Minerva Med http://www.kidney.de/pget.php?&tw=1&pmid=32407051 #FOAvip Currently, there are no approved specific antiviral agents for novel coronavirus disease (COVID-19). Hyper-immune/convalescent plasma derived from recently recovered donors seems to be useful to treat COVID-19 patients, an addition to maximal supportive care and antiviral agents. The endpoints are the improvement of clinical symptoms and laboratory parameters of these patients. However, the efficacy of hyper-immune/convalescent plasma treatment for severe infectious diseases is still controversial. The optimal dose and time point, as well as the clinical benefit of hyper-immune/convalescent plasma therapy, needs further investigation in larger well-controlled trials. Twit Text FOAVip Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19 ????Minerva Med http://www.kidney.de/pget.php?&tw=1&pmid=32407051 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32407051 #FOAvip English Wikipedia <ref>{{Cite pmid|32407051}}</ref> Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19? #MMPMID32407051 Saverino D Minerva Med 2020[Aug]; 111 (4): 362-364 PMID32407051show ga Currently, there are no approved specific antiviral agents for novel coronavirus disease (COVID-19). Hyper-immune/convalescent plasma derived from recently recovered donors seems to be useful to treat COVID-19 patients, an addition to maximal supportive care and antiviral agents. The endpoints are the improvement of clinical symptoms and laboratory parameters of these patients. However, the efficacy of hyper-immune/convalescent plasma treatment for severe infectious diseases is still controversial. The optimal dose and time point, as well as the clinical benefit of hyper-immune/convalescent plasma therapy, needs further investigation in larger well-controlled trials. |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Coronavirus Infections/*therapy[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Pandemics[MESH] |Pneumonia, Viral/*therapy[MESH]Hyper-immune/convalescent plasma: an old option and a valid strategy f(epmc).pdf DeepDyve Pubget Overpricing